Agios Pharma (AGIO) Tops Q2 EPS by 36c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Agios Pharma (AGIO) PT Raised to $89 at Needham & Company
August 2, 2018 11:51 AM EDTNeedham & Company raised its price target on Agios Pharma (NASDAQ: AGIO) to $89.00 (from $86.00) while maintaining a Buy rating.
Analyst Chad Messer commented, "Both TIBSOVO and IDHIFA are now approved in relapsed/refractory AML. Agios is focused on moving both drugs into earlier... More
